Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:CLLS

Cellectis Q1 2026 Earnings Report

Cellectis logo
$3.76 +0.06 (+1.62%)
Closing price 04:00 PM Eastern
Extended Trading
$3.76 +0.01 (+0.13%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Cellectis EPS Results

Actual EPS
N/A
Consensus EPS
-$0.26
Beat/Miss
N/A
One Year Ago EPS
N/A

Cellectis Revenue Results

Actual Revenue
N/A
Expected Revenue
$11.04 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cellectis Announcement Details

Quarter
Q1 2026
Date
5/18/2026
Time
After Market Closes
Conference Call Date
Monday, May 11, 2026
Conference Call Time
2:00AM ET

Conference Call Resources

Cellectis Earnings Headlines

Cellectis to Report First Quarter Financial Results on May 11, 2026
May 4 at 4:30 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/04/3287174/0/en/cellectis-to-report-first-quarter-financial-results-on-may-11-2026.html
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
April 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/27/3282051/0/en/cellectis-presents-epigenetic-editing-platform-to-turn-genes-off-without-altering-dna-at-the-asgct-annual-meeting.html
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
May 5 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
April 13, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GlobeNewswire/1282119/cema-cel-pivotal-trial-interim-data-highlight-strength-of-cellectis-allogeneic-car-t-platform/
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T Platform
April 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/13/3272912/0/en/cema-cel-pivotal-trial-interim-data-highlight-strength-of-cellectis-allogeneic-car-t-platform.html
Monthly information on share capital and company voting rights
April 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/07/3269651/0/en/monthly-information-on-share-capital-and-company-voting-rights.html
See More Cellectis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cellectis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cellectis and other key companies, straight to your email.

About Cellectis

Cellectis (NASDAQ:CLLS) is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies. Its pipeline includes multiple CAR‐T candidates, such as those targeting CD19 and CD22 antigens for B‐cell malignancies and other programs addressing acute myeloid leukemia. Cellectis advances these investigational therapies through preclinical research and early‐ to mid‐stage clinical trials, often in partnership with leading pharmaceutical firms to enhance development and commercialization capabilities.

Cellectis operates research and process development laboratories as well as GMP manufacturing facilities across Europe and North America. Clinical trials are conducted in premier cancer centers in the United States and Europe, reflecting the company’s global reach. Strategic collaborations and licensing agreements support the expansion of its gene‐edited therapies into new indications and geographic markets, with an emphasis on scalable production and regulatory readiness.

Under the leadership of founder and Chief Executive Officer Dr. André Choulika, Cellectis has established itself as a pioneer in TALEN‐based genome editing. The management team combines scientific and commercial expertise to drive innovation, with a focus on delivering next‐generation allogeneic CAR‐T therapies to patients worldwide.

View Cellectis Profile
Earnings Tools